InvAscent, a healthcare-focused private equity firm, has announced the final close of its fourth fund, India Life Sciences Fund IV (ILSF IV), at $305 million. Although this falls short of its initial target, the fund continues InvAscent's commitment to investing in India's life sciences sector.
Strategic Investments from ILSF IV
Since its inception, ILSF IV has been actively deploying capital across various segments of the healthcare industry:
Maiva Pharma: In May 2024, InvAscent, in partnership with Morgan Stanley Private Equity Asia, invested INR 1,000 crore (~$120 million) in Maiva Pharma, India's second-largest pure-play injectables Contract Development and Manufacturing Organization (CDMO). The funds are earmarked for establishing a new manufacturing facility near Hosur, enhancing Maiva's capabilities in sterile dosage forms, including pre-filled syringes and oncology injectables.
Geri Care Health Services: In January 2025, InvAscent led a ₹110 crore (~$13 million) funding round in Geri Care, India's pioneer in integrated geriatric care. The investment aims to expand Geri Care's services across key Southern Indian cities, including Bengaluru, Hyderabad, Kochi, and Coimbatore.
ABI Health Technologies: In December 2023, InvAscent invested $10 million in ABI Health Technologies, a Bangalore-based health-tech SaaS company. ABI's flagship product, ClaimBook, automates hospitals' health insurance claims management processes and has been implemented in over 300 hospitals across India.
InvAscent's Track Record
Founded in 2005, InvAscent has established itself as a leading investor in India's life sciences sector. With assets under management exceeding $800 million, the firm has invested in over 35 companies across pharmaceuticals, healthcare delivery, medical devices, animal health, nutraceuticals, and healthtech industries.
The successful close of ILSF IV, despite falling short of its target, underscores InvAscent's sustained commitment to fostering growth and innovation in India's healthcare landscape.
Source: dealstreetasia
#healthtechstartup #dseidehealthcarenetwork
Strategic Investments from ILSF IV
Since its inception, ILSF IV has been actively deploying capital across various segments of the healthcare industry:
Maiva Pharma: In May 2024, InvAscent, in partnership with Morgan Stanley Private Equity Asia, invested INR 1,000 crore (~$120 million) in Maiva Pharma, India's second-largest pure-play injectables Contract Development and Manufacturing Organization (CDMO). The funds are earmarked for establishing a new manufacturing facility near Hosur, enhancing Maiva's capabilities in sterile dosage forms, including pre-filled syringes and oncology injectables.
Geri Care Health Services: In January 2025, InvAscent led a ₹110 crore (~$13 million) funding round in Geri Care, India's pioneer in integrated geriatric care. The investment aims to expand Geri Care's services across key Southern Indian cities, including Bengaluru, Hyderabad, Kochi, and Coimbatore.
ABI Health Technologies: In December 2023, InvAscent invested $10 million in ABI Health Technologies, a Bangalore-based health-tech SaaS company. ABI's flagship product, ClaimBook, automates hospitals' health insurance claims management processes and has been implemented in over 300 hospitals across India.
InvAscent's Track Record
Founded in 2005, InvAscent has established itself as a leading investor in India's life sciences sector. With assets under management exceeding $800 million, the firm has invested in over 35 companies across pharmaceuticals, healthcare delivery, medical devices, animal health, nutraceuticals, and healthtech industries.
The successful close of ILSF IV, despite falling short of its target, underscores InvAscent's sustained commitment to fostering growth and innovation in India's healthcare landscape.
Source: dealstreetasia
#healthtechstartup #dseidehealthcarenetwork
InvAscent, a healthcare-focused private equity firm, has announced the final close of its fourth fund, India Life Sciences Fund IV (ILSF IV), at $305 million. Although this falls short of its initial target, the fund continues InvAscent's commitment to investing in India's life sciences sector.
Strategic Investments from ILSF IV
Since its inception, ILSF IV has been actively deploying capital across various segments of the healthcare industry:
Maiva Pharma: In May 2024, InvAscent, in partnership with Morgan Stanley Private Equity Asia, invested INR 1,000 crore (~$120 million) in Maiva Pharma, India's second-largest pure-play injectables Contract Development and Manufacturing Organization (CDMO). The funds are earmarked for establishing a new manufacturing facility near Hosur, enhancing Maiva's capabilities in sterile dosage forms, including pre-filled syringes and oncology injectables.
Geri Care Health Services: In January 2025, InvAscent led a ₹110 crore (~$13 million) funding round in Geri Care, India's pioneer in integrated geriatric care. The investment aims to expand Geri Care's services across key Southern Indian cities, including Bengaluru, Hyderabad, Kochi, and Coimbatore.
ABI Health Technologies: In December 2023, InvAscent invested $10 million in ABI Health Technologies, a Bangalore-based health-tech SaaS company. ABI's flagship product, ClaimBook, automates hospitals' health insurance claims management processes and has been implemented in over 300 hospitals across India.
InvAscent's Track Record
Founded in 2005, InvAscent has established itself as a leading investor in India's life sciences sector. With assets under management exceeding $800 million, the firm has invested in over 35 companies across pharmaceuticals, healthcare delivery, medical devices, animal health, nutraceuticals, and healthtech industries.
The successful close of ILSF IV, despite falling short of its target, underscores InvAscent's sustained commitment to fostering growth and innovation in India's healthcare landscape.
Source: dealstreetasia
#healthtechstartup #dseidehealthcarenetwork
